Skip to main content
BCDA logo

BCDA · BioCardia, Inc.

Track BCDA — free
$0.73 -0.04 (-5.24%)
Market Cap
$11.70M
Shares
15.14M
Volume · Nov 19 157.43K Avg daily vol (3M) 202.25K

Price & Indicators

 

Key stats

Close
$0.77
Open
$0.79
Day range
$0.73–0.80
52-week closing range
$0.77–1.47
Average volume, 30 days
113K
Short interest
735K · 4.9% of shares · 6.3 days
Short volume, last session
80%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Mar 23, 2027 Est · unconfirmed · in 18 wks

Latest documents

2026
Nov 12
Earnings call
Japan filing advances with $2.2 million cash and 2027 runway

Biocardia says Japan filing work is progressing, FDA feedback on Helix is expected within six weeks, and a potential de novo submission is targeted for first quarter of 2027. It ended with $2.2 million in cash, providing runway into 2027.

5 source passages
Biocardia is fully committed to the post-marketing study launch in Japan with our expertise, but we do recognize the value that a partner has for long-term growth in Japan and the Asia-Pacific region. We have answered all of these questions to Japan's Pharmaceuticals and Medical Devices Agency satisfaction, and we are proceeding to Shonen's submission with our designated marketing authorization holder. We expect to hear from the FDA on this pre-submission in the next six weeks. If the FDA supports the de novo approval pathway for Helix, we expect to complete the de novo submission in the first quarter of 2027 We ended the quarter with cash and cash equivalents totaling $2.2 million, providing runway into 2027. Open the document at this passage
Nov 12
Current report 8-K
Quarterly net loss rises to $1.8 million as cash reaches $2.2 million

BioCardia reported a $1.8 million net loss for the three months ended September 2026 and ended the quarter with $2.2 million in cash and cash equivalents, providing anticipated runway into 2027.

Financial results
3 source passages
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results Our net loss was $1.8 million for the three months ended September 2026 compared to $1.5 million for the three months ended September 2025. The Company ended the quarter with cash and cash equivalents totaling $2.2 million, providing anticipated runway into 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $2.2 million funds operations only through January 2027

BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.

Net loss $1.82M
Read from the first part of this long document
3 source passages
BioCardia, Inc. (we, us, our, BioCardia or the Company), is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Therefore, absent additional funding, management believes our cash and cash equivalents of approximately $2.2 million as of September 30, 2026 are not sufficient to fund our planned expenditures and meet our obligations beyond January 2027. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. Open the document at this passage
Nov 6
Current report 8-K
CardiAMP advances toward Japanese marketing application

BioCardia completed consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), advancing the CardiAMP Cell Therapy System toward a marketing approval application in Japan. Completion does not constitute regulatory approval, and PMDA review remains outstanding.

Other events
2 source passages
BioCardia® , Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System ("CardiAMP") for the treatment of ischemic heart failure. Completion of the consultation process does not constitute regulatory approval. The CardiAMP Cell Therapy System remains subject to PMDA review and applicable Japanese regulatory requirements. Open the document at this passage
Oct 19
Current report 8-K
Other events

BioCardia announced the FDA accepted its De Novo pre-submission package for marketing clearance of the Helix catheter, with substantive review and a meeting expected this quarter.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$7.67M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-65.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.22M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+133.2%
Year over year · more shares
Price change (1Y)
-41.5%
Trailing year
Short interest
4.9%
Latest settlement · 6.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. BioCardia advanced its Japan and Helix regulatory paths, reduced nine-month net loss, ended the quarter with cash providing runway into 2027, and continued expanding trial and imaging development. However, regulatory timing and funding remain risks, while Q3 net loss, nine-month operating cash use, and quarterly R&D expenses increased.

Bullish
  • + Biocardia answered PMDA's remaining questions to the agency's satisfaction and is proceeding with the Japan Shonin submission. new
  • + If FDA supports the de novo pathway, BioCardia expects to complete the Helix submission in the first quarter of 2027 and receive approval in mid-2027. new
  • + Nine-month net loss decreased to $5.7 million from $6.2 million, primarily due to lower research and development expenses. new
  • + The CardiAMP Heart Failure II trial has four actively recruiting sites, seven additional sites are being onboarded, and management is aware of no safety issues. new
  • + BioCardia ended the quarter with $2.2 million of cash and cash equivalents, providing anticipated runway into 2027. new
  • + BioCardia is working with CART-Tech to advance the Heart3D platform into the clinic in 2027. new
Bearish
  • − The Japan submission timeline faces a risk that product documentation may require additional testing or work. new
  • − BioCardia may need further discussions with FDA if the agency does not support the Helix de novo approval pathway. new
  • − Q3 net loss increased to $1.8 million from $1.5 million. new
  • − Net cash used in operations for the first nine months increased to $5.1 million from $4.9 million. new
  • − Q3 research and development expenses increased to $1.2 million from $0.9 million. new
  • − BioCardia faces the risk of being unable to raise additional funding needed to continue its product development plans. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −21%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −16%
trailing
YTD return −38%
this year
Relative strength −10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Accumulating
Net +$4.4K over 90 days · 0% sells
Short interest Rising
4.86% of shares out · ▲ +8.4% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
Revenue growth −17%
Y/Y
Gross margin 13%
expanding
Free cash flow $-7.4M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −48%
past year
ATR 12.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Accumulating
Net +$4.4K over 90 days · 0% sells
Short interest Rising
4.86% of shares out · ▲ +8.4% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $1
vs 200-day avg -26% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Net cash used in operations $5.1M nine months ended September 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCDA
BioCardia, Inc.
this stock
$11.70M -38.2% -16.8% — 4.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
21
% held
9.5%
Net QoQ
+98.7K sh
Top holder
CM Management, LLC
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
735.1K
Days to cover
6.3d
Change
+56.7K sh
View
Short Volume
Short vol %
80%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.4K
Value
$4.5K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
63.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$4.4K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$479.0K
Net income (FY)
$-8.2M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
32

BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.

View
Proposed Sales
Value
$6.6K
Shares
3.3K
Filed
Dec 17, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
BioCardia Reports Third Quarter 2…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
BCDA -6.5% -16.8% -16.0% -10.3% -38.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -1.0% -10.5% -10.4% -5.0% -43.2%
Key facts CIK 925741 CUSIP 09060U606 13F (30d) 21 filings 21 filers Visit website Investor relations